Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $11.80.

CMPX has been the subject of a number of research reports. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. D. Boral Capital restated a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. Finally, Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $5.00 to $4.00 in a report on Friday, November 15th.

Compass Therapeutics Stock Performance

Compass Therapeutics stock opened at $2.61 on Friday. Compass Therapeutics has a 52 week low of $0.76 and a 52 week high of $2.73. The firm has a market cap of $359.11 million, a P/E ratio of -7.05 and a beta of 0.92. The business’s fifty day moving average is $1.65 and its two-hundred day moving average is $1.53.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. On average, equities research analysts predict that Compass Therapeutics will post -0.35 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Rovin Capital UT ADV bought a new position in Compass Therapeutics during the 3rd quarter worth approximately $25,000. Intech Investment Management LLC bought a new position in shares of Compass Therapeutics during the third quarter worth $30,000. XTX Topco Ltd acquired a new position in shares of Compass Therapeutics in the 3rd quarter valued at $37,000. Cubist Systematic Strategies LLC bought a new stake in shares of Compass Therapeutics in the 2nd quarter valued at $41,000. Finally, SG Americas Securities LLC raised its stake in Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after buying an additional 5,515 shares during the period. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.